Tango Therapeutics closed at $23.18 on Nov 4, up 0.04%, 29.5% below its 52-week closing high. Volume of 2.5M shares was 0.53× its 20-day average (below normal).
Split-adjusted performance: +5.8% over one month, -1.9% over six months, +189.4% over one year.
Short interest was 44.8M shares at the Oct 15 settlement (31.9% of float, 11.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TNGXTango Therapeutics | $23.18 | +0.04% | −1.9% | −100.0% | — | — | $3.91B | |
| ABCLAbCellera Biologics | $12.28 | +0.82% | +143.7% | −76.3% | −1368.6% | — | $3.98B | Compare |
| XENEXenon Pharmaceuticals | $39.19 | +2.51% | −33.1% | — | — | — | $3.80B | Compare |
| PBLSParabilis Medicines | $30.36 | +3.79% | — | — | −45239.9% | — | $3.75B | Compare |
| EWTXEdgewise Therapeutics | $37.53 | −0.40% | +1.5% | — | — | — | $4.08B | Compare |
| ACADAcadia Pharmaceuticals | $21.47 | +4.38% | 0.0% | +16.4% | 10.2% | 9.7 | $3.70B | Compare |
| IRONDisc Medicine | $83.28 | +2.61% | +21.3% | — | — | — | $3.70B | Compare |
| AMLXAmylyx Pharmaceuticals | $29.40 | +0.68% | +83.1% | — | — | — | $3.69B | Compare |
| OGNOrganon & | $13.83 | −0.14% | +3.1% | −1.7% | 10.4% | 17.1 | $3.63B | Compare |
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
